Carbon monoxide poisoning is a frequent domestic accident and the leading cause of death from unintentionnal poisoning. Its toxicity is based on the CO binding to hemoglobin and myoglobin, inhibition of mitochondrial cytochrome oxidase, resulting in tissue hypoxia and reduced adenosine triphosphate synthesis and ischemia-reperfusion injury.
This study aims to investigate the early and late cardiologic effects of CO in patients treated with hyperbaric oxygen (HBOT) for CO poisoning
None
refusal
All patients treated for CO poisoning with HBOT following European and French recommendations in our department from 2015/01/01 to 2021/12/31
Cohort
Retrospective
Not listed
early and late cardiac injury due to CO poisoning description
clinical manifestation, troponin elevation and/or ECG abnormality during acute CO poisoning description; then late cardiac manifestation and abnormality declared by patients who have had early cardiac abnormality (troponin elevation and/or ECG abnormalities)
relationship between the source of CO poisoning and cardiac injury
comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between context of poisoning (domestic, professionnal or intentional poisoning) and cardiac injury
comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between other possibly associated poisoning and cardiac injury
comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
relationship between severity of neurological symptoms and cardiac injury
comparison between the group of patients with early cardiac abnormalities (troponin elevation and/or ECG abnormalities) and the group of patients without early cardiac abnormalities using Ficher test
Click on the lead sponsor to view all of their trials.
